Home » Topics » Regulatory » EMA

EMA
RSS

Orbus Therapeutics' brain cancer drug receives EMA orphan medicinal product status

June 20, 2016

GM-604 receives E.U. orphan drug designation for ALS

June 10, 2016

Protalix BioTherapeutics initiates global phase III study of PRX-102 in Fabry disease

June 7, 2016

Kite Pharma granted access to European PRIME initiative for KTE-C19 in DLBCL

June 2, 2016

Can-Fite reaches agreement with EMA for piclidenoson phase III trial

June 2, 2016

CCX-168 receives EMA PRIME designation for AAV

June 2, 2016

QR-110 from ProQR Therapeutics receives U.S. and E.U. orphan drug designations

June 2, 2016

EMA committee supports expanding approval of Tysabri

June 1, 2016

BioMarin withdraws Kyndrisa MAA, discontinues development of follow-on products

June 1, 2016

Simponi receives positive opinion in Europe for treatment of pJIA

May 31, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...